Aug 24, 2026
Moderna (MRNA) Stock Skyrockets 177% on Melanoma Vaccine Breakthrough – Can It Last?
Moderna (MRNA) stock exploded 177% on melanoma vaccine trial success, marking the biggest S&P 500 gain in 20+ years. Analysts question if it's sustainable.
The post Moderna (MRNA) Stock Skyrockets 177% on Melanoma Vaccine Breakthrough – Can It Last? appeared first on Blockonomi.
Source: Blockonomi →Related News
- 1 hour ago
Coherent Corp. (COHR) Stock: Surge as New 6.4T Optics Boost AI Growth Outlook
- 1 hour ago
International Business Machines Corporation (IBM) Stock: New Study Reveals AI Wo...
- 1 hour ago
GRAIL (GRAL) Stock Surges 22% Before Critical FDA Panel Meeting on Galleri Test
- 1 hour ago
Solidion Technology (STI) Stock: Climbs as CEO Jaymes Winters Adds Chairman Role
- 1 hour ago
Accenture (ACN) Stock Surges 6% Following $2B Anthropic AI Safety Deal